pAG8Ha-SERBP1(149-400)
(Plasmid
#176516)
-
PurposeExpresses the human C-terminal SERBP1 149-400 construct.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 176516 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepAG8Ha
- Backbone size w/o insert (bp) 5000
- Total vector size (bp) 5760
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameSERBP1 149-400
-
Alt nameSERPINE1 mRNA binding protein 1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)760
-
Mutationdeleted amino acids 1-148 and 401-408
-
GenBank IDNM_001018067.2
-
Entrez GeneSERBP1 (a.k.a. CGI-55, CHD3IP, HABP4L, PAI-RBP1, PAIRBP1)
- Promoter T7
-
Tag
/ Fusion Protein
- His8 tag, linker, TEV site (N terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site KasI (unknown if destroyed)
- 3′ cloning site BamHI (unknown if destroyed)
- 5′ sequencing primer T7
- 3′ sequencing primer T7 reverse (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pAG8Ha-SERBP1(149-400) was a gift from David Libich (Addgene plasmid # 176516 ; http://n2t.net/addgene:176516 ; RRID:Addgene_176516) -
For your References section:
Structural Characterization of the RNA-Binding Protein SERBP1 Reveals Intrinsic Disorder and Atypical RNA Binding Modes. Baudin A, Moreno-Romero AK, Xu X, Selig EE, Penalva LOF, Libich DS. Front Mol Biosci. 2021 Sep 24;8:744707. doi: 10.3389/fmolb.2021.744707. eCollection 2021. 10.3389/fmolb.2021.744707 PubMed 34631798